Table 1.
Comprehensive Overview of the Study Cohort and Statistical Contribution to the Classifiers
| Cohort | Group | n | Acc. (%) | AUC (95% CI) | No. with Inflammatory Disease | Median Age (IQR) | Blood Storage (% <12 hr) | Statistical Predictive Contribution Likelihood Ratio Chi-Square Value (p Value) |
||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient Age | Blood Storage | Gender | Smoking | thromboSeq Classification | ||||||||
| Unmatched Cohort (Best et al., 2015) | ||||||||||||
| Training (unmatched) | healthy | 39 | 92 | 0.99 (0.97–1.00) | 0 | 40 (22.25) | 100 | 9.8 (p = 0.002) | 2.9 (p = 0.09) | 0.8 (p = 0.38) | NA | 29.5 (p < 0.0001) |
| NSCLC | 36 | NA | 59 (13.25) | 61 | ||||||||
| Validation (unmatched) |
healthy | 16 | 98 |
0.98 (0.93–1.00) |
0 | 32.5 (26.25) | 100 | 0.004 (p = 0.95) |
0.01 (p = 0.90) |
3.5 (p = 0.06) |
NA |
21.6 (p < 0.0001) |
| NSCLC | 24 | NA | 62 (14.25) | 58 | ||||||||
| Matched Cohort (This Study) Genes: n = 830 | ||||||||||||
| Training (matched) | non-cancer | 44 | 77 | 0.84 (0.75–0.92) | 36 | 62 (18.5) | 100 | 2.4 (p = 0.12) | NA | 0.03 (p = 0.87) | 5.7 (p = 0.12) | 30.7 (p < 0.0001) |
| NSCLC | 49 | NA | 59 (9) | 100 | ||||||||
| Evaluation (matched) | non-cancer | 20 | 85 | 0.91 (0.82–1.00) | 4 | 61 (10.25) | 100 | 4.1 (p = 0.04) | NA | 0.05 (p = 0.80) | 6.0 (p = 0.11) | 32.0 (p < 0.0001) |
| NSCLC | 20 | NA | 58 (24) | 100 | ||||||||
| Validation (matched) |
non-cancer | 40 | 91 |
0.95 (0.91–0.99) |
9 | 56 (9.25) | 100 | 3.7 (p = 0.06) |
NA |
0.1 (p = 0.95) |
14.7 (p = 0.002) |
76.2 (p < 0.0001) |
| NSCLC | 90 | NA | 63 (14) | 100 | ||||||||
| Full Cohort (This Study) Genes: n = 1,000 | ||||||||||||
| Training (matched) | non-cancer | 60 | 84 | 0.90 (0.84–0.95) | 30 | 59 (9.25) | 100 | <0.0001 (p = 0.99) | NA | 3.4 (p = 0.18) | 2.7 (p = 0.43) | 58.7 (p < 0.0001) |
| NSCLC | 60 | NA | 61 (13.25) | 100 | ||||||||
| Evaluation (matched) | non-cancer | 44 | 91 | 0.93 (0.87–0.99) | 19 | 58 (15.5) | 100 | 0.62 (p = 0.43) | NA | 1.1 (p = 0.30) | 9.9 (p = 0.02) | 55.0 (p < 0.0001) |
| NSCLC | 44 | NA | 62 (13) | 100 | ||||||||
| Late-stage validation (unmatched) | non-cancer | 273 | 88 | 0.94 (0.92–0.96) | 94 | 40 (20) | 97 | 39.6 (p < 0.0001) | 0.07 (p = 0.80) | 0.19 (p = 0.67) | 33.5 (p < 0.0001) | 91.5 (p < 0.0001) |
| NSCLC | 245 | NA | 64 (14) | 75 | ||||||||
| Loc.-adv. validation (unmatched) | non-cancer | 53 | 81 | 0.89 (0.83–0.95) | 8 | 53 (12) | 98 | 23.4 (p < 0.0001) | 4.5 (p = 0.03) | 3.6 (p = 0.06) | 25.6 (p < 0.0001) | 26.7 (p < 0.0001) |
| NSCLC | 53 | NA | 62 (11) | 83 | ||||||||
NA, not applicable. See also Table S1.